Active ingredientCrenolanibCat. No. P-C254-001CAS 670220-88-9Family · Pharmaceutical analytical standards
Crenolanib
An experimental oral benzimidazole that blocks the FLT3 and PDGFR kinases: in clinical trials since the late 2000s, it is studied mainly in acute myeloid leukaemia with FLT3 mutations and in gastrointestinal stromal tumours (GIST) with the PDGFRA D842V mutation. This family brings together the active ingredient.
Did you know?Unlike inhibitors such as imatinib and sorafenib, which are 'type II', it is a 'type I' inhibitor: it latches onto the enzyme in its active form, and so also binds tightly to FLT3 carrying D835 mutations.
Go to the active ingredient →Active ingredientCrenolanibCat. No. P-C254-001CAS 670220-88-9No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.